KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2025)

Historic Raw Materials for Sarepta Therapeutics (SRPT) over the last 10 years, with Q3 2025 value amounting to $325.5 million.

  • Sarepta Therapeutics' Raw Materials rose 5626.97% to $325.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.5 million, marking a year-over-year increase of 5626.97%. This contributed to the annual value of $280.0 million for FY2024, which is 10904.65% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Raw Materials stood at $325.5 million for Q3 2025, which was up 5626.97% from $314.9 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Raw Materials high stood at $325.5 million for Q3 2025, and its period low was $59.2 million during Q4 2022.
  • Over the past 5 years, Sarepta Therapeutics' median Raw Materials value was $239.7 million (recorded in 2023), while the average stood at $222.2 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Raw Materials tumbled by 7429.08% in 2022, and later surged by 12636.15% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Raw Materials (Quarter) stood at $230.2 million in 2021, then plummeted by 74.29% to $59.2 million in 2022, then soared by 126.36% to $134.0 million in 2023, then surged by 109.05% to $280.0 million in 2024, then rose by 16.25% to $325.5 million in 2025.
  • Its Raw Materials stands at $325.5 million for Q3 2025, versus $314.9 million for Q2 2025 and $299.0 million for Q1 2025.